心肌缺血/再灌注损伤中炎症反应作用机制的研究进展

被引:11
作者
孟秋宏
王剑波
机构
[1] 第四军医大学药学院药物研究所
关键词
心肌; 缺血再灌注; 炎症; 分子机制; 信号通路;
D O I
暂无
中图分类号
R541 [心脏疾病];
学科分类号
100201 [内科学];
摘要
<正>心肌缺血/再灌注(I/R)损伤是指心肌组织缺血后恢复血流.血液的再灌注不能使其功能恢复,反而加重其结构损伤和功能障碍的病理生理过程[1]。最终可能导致心肌梗塞、纤维化、心肌肥厚和心力衰竭。心肌L/R损伤的发生发展机制复杂。涉及到多系统多环节的异常,而炎症反应伴随其全过程,其中钙超载、活性氧(ROS)产生、中性粒细胞浸润和补体激活均参与调节心肌VR损伤的炎症反应[1]。因此,进一步了解炎症因子和相关信号通路在心肌VR损伤中的作用,对该病的防治具有十分重要的理论和应用价值。一、I/R损伤后心肌炎症相关的分子机制和信号通路
引用
收藏
页码:214 / 216
页数:3
相关论文
共 16 条
[1]
Mechanisms and Consequences of Inflammatory Signaling in the Myocardium [J].
Ahn, Jihyun ;
Kim, Jaetaek .
CURRENT HYPERTENSION REPORTS, 2012, 14 (06) :510-516
[2]
Inflammation in Myocardial Diseases [J].
Marchant, David J. ;
Boyd, John H. ;
Lin, David C. ;
Granville, David J. ;
Garmaroudi, Farshid S. ;
McManus, Bruce M. .
CIRCULATION RESEARCH, 2012, 110 (01) :126-144
[3]
Effect of CC Chemokine Receptor 2 CCR2 Blockade on Serum C-Reactive Protein in Individuals at Atherosclerotic Risk and With a Single Nucleotide Polymorphism of the Monocyte Chemoattractant Protein-1 Promoter Region [J].
Gilbert, Jim ;
Lekstrom-Himes, Julie ;
Donaldson, Debra ;
Lee, Yih ;
Hu, Mingxiu ;
Xu, Jing ;
Wyant, Tim ;
Davidson, Michael .
AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (06) :906-911
[4]
Inflammasome Activation of Cardiac Fibroblasts Is Essential for Myocardial Ischemia/Reperfusion Injury [J].
Kawaguchi, Masanori ;
Takahashi, Masafumi ;
Hata, Takeki ;
Kashima, Yuichiro ;
Usui, Fumitake ;
Morimoto, Hajime ;
Izawa, Atsushi ;
Takahashi, Yasuko ;
Masumoto, Junya ;
Koyama, Jun ;
Hongo, Minoru ;
Noda, Tetsuo ;
Nakayama, Jun ;
Sagara, Junji ;
Taniguchi, Shun'ichiro ;
Ikeda, Uichi .
CIRCULATION, 2011, 123 (06) :594-+
[5]
Protease-Activated Receptor 2 Deficiency Reduces Cardiac Ischemia/Reperfusion Injury [J].
Antoniak, Silvio ;
Rojas, Mauricio ;
Spring, Denise ;
Bullard, Tara A. ;
Verrier, Edward D. ;
Blaxall, Burns C. ;
Mackman, Nigel ;
Pawlinski, Rafal .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (11) :2136-2142
[6]
Clarithromycin attenuates myocardial ischemia–reperfusion injury.[J].Takuya Nakajima;Keiichi Hishikari;Masahito Ogawa;Ryo Watanabe;Jun-ichi Suzuki;Ayako Nagashima;Mayumi Masumura;Kiyoshi Takayama;Yasunobu Hirata;Ryozo Nagai;Mitsuaki Isobe.Expert Opinion on Therapeutic Targets.2010, 9
[7]
Immunoregulatory Effects of Carvedilol on Rat Experimental Autoimmune Myocarditis.[J].H.Liu;W.Li;W.Gu;Y.Kong;N.Yang;L.Chen.Scandinavian Journal of Immunology.2009, 1
[8]
Effect of the Soluble TNF-Antagonist Etanercept on Tumor Necrosis Factor Bioactivity and Stability [J].
Mann, Douglas L. ;
Bozkurt, Biykem ;
Torre-Amione, Guillermo ;
Soran, Ozlem Z. ;
Sivasubramanian, Natarajan .
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2008, 1 (02) :142-145
[9]
SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts [J].
Strande, Jennifer L. ;
Hsu, Anna ;
Su, Jidong ;
Fu, Xiangping ;
Gross, Garrett J. ;
Baker, John E. .
BASIC RESEARCH IN CARDIOLOGY, 2007, 102 (04) :350-358
[10]
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].
Chung, ES ;
Packer, M ;
Lo, KH ;
Fasanmade, AA ;
Willerson, JT .
CIRCULATION, 2003, 107 (25) :3133-3140